Quantcast

Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr Instagram
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
October 24, 2014, 11:38:09 AM

Login with username, password and session length


Members
Stats
  • Total Posts: 643407
  • Total Topics: 48957
  • Online Today: 183
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Study finds potential way to make an AIDS vaccine  (Read 971 times)

0 Members and 1 Guest are viewing this topic.

Offline wonderful1

  • Member
  • Posts: 18
Study finds potential way to make an AIDS vaccine
« on: December 28, 2010, 04:43:17 PM »
http://www.canada.com/business/fp/Study+finds+potential+make+AIDS+vaccine/1959462/story.html?id=1959462

WASHINGTON - The discovery of immune system particles that attack the AIDS virus may finally open a way to make a vaccine that could protect people against the deadly and incurable infection, U.S. researchers said on Thursday.

They used new technology to troll through the blood of 1,800 people infected with the AIDS virus and identified two immune system compounds called antibodies that could neutralize the virus.

And they found a new part of the virus that the antibodies attack, offering a new way to design a vaccine, they reported in the journal Science.

"So now we may have a better chance of designing a vaccine that will elicit such broadly neutralizing antibodies, which we think are key to successful vaccine development," said Dennis Burton of The Scripps Research Institute in La Jolla, California, who led the study.

"The findings themselves are an exciting advance toward the goal of an effective AIDS vaccine because now we've got a new, potentially better target on HIV to focus our efforts for vaccine design," added Wayne Koff of the International AIDS Vaccine Initiative, or IAVI, which sponsored the study.

Since the AIDS pandemic started in the early 1980s, more than 25 million people globally have died from the virus. The World Health Organization estimates that 33 million are currently infected.

There is no cure, although a cocktail of drugs can help keep the virus under control. Efforts to make a vaccine have failed almost completely.

MUTABLE VIRUS

Part of this is because the virus mutates so much that any one person is infected with millions of different versions, each one appearing different to the immune system.

In addition, the virus infects the very immune cells that are supposed to help protect the body. And if even one virus gets past the immune defense, it appears to set up a lifelong infection. No drug has been able to eradicate it.

IAVI director Dr. Seth Berkley said the findings will not lead directly to a vaccine, but show that there are new and better ways to design one.

He said 10 percent of the patients whose blood was screened had a strong antibody response to the virus. "We have people with even more potent serum out there. We will probably see more," he said in a telephone interview.

It may also be possible to use such antibodies as therapy themselves -- such as the gamma globulin used for hepatitis virus. But the eventual goal, Berkley said, is a vaccine that produces antibodies that could stop the virus from ever infecting a person in the first place.

"We haven't been able to do that because we haven't been able to find the right kind of response," Berkley said.

Most vaccines elicit an antibody response, priming the body to make antibodies that will recognize and attack an invader such as a bacteria or virus.

The two antibodies, called PG9 and PG16, are the first new HIV antibodies to have been identified in more than 10 years. They target a region of the spike the virus uses to infect cells, the researchers wrote.

A team at South San Francisco-based Monogram Biosciences Inc screened the blood for the ability to neutralize HIV. Theraclone Sciences used its technology to identify the antibodies involved.

North Carolina-based Laboratory Corp of America Holdings acquired Monogram in July.

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.